Trypanosoma cruzi CYP51 inhibitor derived from a Mycobacterium tuberculosis screen hit.

• Main Authors: Chiung-Kuang Chen (Author), Patricia S Doyle (Author), Liudmila V Yermalitskaya (Author), Zachary B Mackey (Author), Kenny K H Ang (Author), James H McKerrow (Author), Larissa M Podust (Author)
• Format: Book
• Published: Public Library of Science (PLoS), 2009-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

BACKGROUND:The two front-line drugs for chronic Trypanosoma cruzi infections are limited by adverse side-effects and declining efficacy. One potential new target for Chagas' disease chemotherapy is sterol 14alpha-demethylase (CYP51), a cytochrome P450 enzyme involved in biosynthesis of membrane...